years. 4 , 5 Covariates Patient demographic and clinical characteristics were compared and used for model adjustment, including age at index diagnosis, race (white, black, other) type of MBC (de novo vs treated, secondary metastatic disease), HR status
Search Results
Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque
Randy C. Miles, Christoph I. Lee, Qin Sun, Aasthaa Bansal, Gary H. Lyman, Jennifer M. Specht, Catherine R. Fedorenko, Mikael Anne Greenwood-Hickman, Scott D. Ramsey, and Janie M. Lee
. Clinical data included age at diagnosis, race, diagnosis year, family history of breast cancer, and breast cancer–specific genetic mutation status. Tumor characteristic data included AJCC stage, grade, size, and estrogen receptor (ER), progesterone receptor
Ayal A. Aizer, Xiangmei Gu, Ming-Hui Chen, Toni K. Choueiri, Neil E. Martin, Jason A. Efstathiou, Andrew S. Hyatt, Powell L. Graham, Quoc-Dien Trinh, Jim C. Hu, and Paul L. Nguyen
cancer and a short life expectancy in the United States. Subjects/Patients and Methods Patient Characteristics and Study Design A population-based study was conducted of patients with low-risk prostate cancer identified by the SEER
Etienne Bastien, Sophie Lefèvre-Arbogast, Justine Lequesne, François Gernier, François Cherifi, Olivier Rigal, Lydia Guittet, Jean‐Michel Grellard, Giulia Binarelli, Marie Lange, Marie Fernette, Laure Tron, Adeline Morel, Doriane Richard, Bénédicte Griffon, Alexandra Leconte, Florian Quilan, Louis-Ferdinand Pépin, Fabrice Jardin, Marianne Leheurteur, Audrey Faveyrial, Bénédicte Clarisse, and Florence Joly
.gov identifier: NCT04366154 ). Results Baseline Characteristics We included 734 patients, including 565 who completed the IES-R. As previously published, no statistically significant differences were observed between sociodemographic and clinical
Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher
delivery of postoperative chemotherapy include clinical factors, such as patient age, extent of postoperative complications, and presence of lymph node metastases. 10 – 13 In contrast, sociodemographic characteristics influencing receipt of adjuvant
Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi
was taking was investigated by a review of the medical records. Table 1 Patient Demographics and Clinical Characteristics (N=106) Depression: Presence/absence of depression was assessed using the PHQ-9. 23 The PHQ-9 consists of 9
Lucia Hämmerl, Nikolaus C.S. Mezger, Tobias P. Seraphin, Walburga Yvonne Joko-Fru, Mirko Griesel, Jana Feuchtner, Franck Gnahatin, Freddy Houéhanou Rodrigue Gnangnon, Nathan Okerosi, Phoebe Mary Amulen, Rolf Hansen, Margaret Ziona Borok, Carla Carrilho, Brahima Mallé, Clausina Ahoui Apendi, Nathan G. Buziba, Edom Seife, Biying Liu, Rafael Mikolajczyk, Donald M. Parkin, Eva J. Kantelhardt, and Ahmedin Jemal
cancer. 20 All patients with stage IV CRC should receive some form of (radio-)chemotherapy, with surgical resection depending on tumor characteristics and patient condition. Radiotherapy in a single fraction is an option for surgically unresectable stage
Rongbo Lin, Sunzhi Lin, Shuitu Feng, Qingyi Wu, Jianqian Fu, Fang Wang, Hui Li, Xiaofeng Li, Gaowang Zhang, Yongzhi Yao, Min Xin, Tianyang Lai, Xia Lv, Yigui Chen, Shangwang Yang, Yubiao Lin, Lixia Hong, Zhenyu Cai, Jianfeng Wang, Gen Lin, Shaowei Lin, Shen Zhao, Jinfeng Zhu, and Cheng Huang
pain control. Median initial dosages in opioid-tolerant patients were 1 mg (IQR, 0.5–2) and 1 mg (IQR, 0.5–2) in the PCA and non-PCA groups, respectively. Baseline characteristics ( Table 1 ) were well balanced between the 2 groups, with comparable ESAS
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
). Patient demographics and clinical characteristics are detailed in Table 1 . Of the patients, 98% were women, 78% were white, and 19.5% were black. Median age was 59.4 years (range, 50.7–67.7 years) at initiation of palbociclib treatment. Most patients (n
Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen
involved CAR T-cell therapy. The most common cancer types were leukemia (16%), lung (12%), and breast (10%) ( Table 1 ). Table 1. Characteristics of Dose-Escalation Trials Of the 3,890 patients, 2,506 had both response and dose data, among whom the ORR (CR
